Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
Status:
Completed
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate if the addition of zanubrutinib to
supportive care increases the respiratory failure-free survival rate at Day 28 in
participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress.